These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 17577041)

  • 1. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
    Sultana A; Smith CT; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
    J Clin Oncol; 2007 Jun; 25(18):2607-15. PubMed ID: 17577041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
    Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D
    Cochrane Database Syst Rev; 2006 Jul; (3):CD002093. PubMed ID: 16855985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
    Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD002093. PubMed ID: 19821291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
    Tu C; Zheng F; Wang JY; Li YY; Qian KQ
    Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
    Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
    PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
    Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
    Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
    Sultana A; Tudur Smith C; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
    Br J Cancer; 2008 Jul; 99(1):6-13. PubMed ID: 18577990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for advanced pancreatic cancer.
    Chua YJ; Cunningham D
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities of palliation in pancreatic cancer].
    Di Costanzo F; Sdrobolini A; Gasperoni S
    Tumori; 1999; 85(1 Suppl 1):S47-53. PubMed ID: 10235081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
    Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
    Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
    Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.